Events & Presentations
Presentations
| Date | Title | Documents |
|---|---|---|
RedHill Biopharma TALICIA Confirmatory Phase III Results Webcast |
|
|
RedHill Biopharma Corporate Presentation |
|
Featured Events
| Date | Event Details | Remind Me |
|---|---|---|
|
Dec 3, 2018
8:30 AM EST |
TALICIA Confirmatory Phase III Top-Line Results Webcast
|
|
|
Nov 13, 2018
8:30 AM EST |
Third Quarter 2018 Financial Results Conference Call
To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call: United States: +1-866-575-6539; International: +1-929-477-0402; and Israel: +972-3-376-1315. The access code for the call is: 2166581. |
|
|
Oct 22, 2018
|
United European Gastroenterology Week (UEG Week 2018)
Vienna, Austria
An abstract discussing the study’s top-line results, ‘A Phase III Randomized, Double Blind, Placebo-Controlled, Multicenter, Parallel Group Study To Assess The Efficacy And Safety Of Add-On Fixed-Dose Anti-Mycobacterial Therapy (RHB-104) In Moderately To Severely Active Crohn's Disease (MAP US)’ was presented as a late-breaking abstract today at the United European Gastroenterology Week (UEG Week 2018) by Dr. David Y. Graham, M.D., Professor of Medicine, Molecular Virology and Microbiology at Baylor College of Medicine, Houston and Lead Investigator of the MAP US study. |
|
|
Jul 30, 2018
|
Webcast – RHB-104 positive Phase III top-line results for Crohn’s disease
|
|
|
Dec 29, 2015
|
Prof. Thomas Borody Interview on Crohn's Disease and Gut Health
|